Insights into Parkinson's balance problems

In PD, disorganized sensorimotor signals cause muscles in the limbs to contract, such that both a muscle promoting a motion and its antagonist muscle are Read more

Cajoling brain cells to dance

“Flicker” treatment is a striking non-pharmaceutical approach aimed at slowing or reversing Alzheimer’s disease. It represents a reversal of EEG: not only recording brain waves, but reaching into the brain and cajoling cells to dance. One neuroscientist commentator called the process "almost too fantastic to believe." With flashing lights and buzzing sounds, researchers think they can get immune cells in the brain to gobble up more amyloid plaques, the characteristic clumps of protein seen in Read more

Parkinson’s Disease

A new class of brain-protecting drugs

Pathologist Keqiang Ye has made a series of discoveries recently, arising from his investigations of substances that can mimic the growth factor BDNF (brain-derived neurotrophic factor).

BDNF is a protein produced by the brain that pushes neurons to withstand stress and make new connections. Some neuroscientists have described BDNF as “Miracle Gro for brain cells.”

“BDNF has been studied extensively for its ability to protect neurons vulnerable to degeneration in several diseases, such as ALS, Parkinson’s and Alzheimer’s disease,” Ye says. “The trouble with BDNF is one of delivery. It’s a protein, so it can’t cross the blood-brain barrier and degrades quickly.”

Working with Ye, postdoctoral fellow Sung-Wuk Jang identified a compound called 7,8-dihydroxyflavone that can duplicate BDNF’s effects on neurons and can protect them against damage in animal models of seizure, stroke and Parkinson’s disease. The compound’s selective effects suggest that it could be the founder of a new class of brain-protecting drugs. The results were published in Proceedings of the National Academy of Sciences.

Read more

Posted on by Quinn Eastman in Neuro 1 Comment

Michael J. Fox Foundation supports Emory research

The Michael J. Fox Foundation for Parkinson’s Research just announced plans to fund Emory pharmacology researcher Zixu Mao in his work to validate therapeutic targets for Parkinson’s disease (PD).

Zixu Mao, PhD

Zixu Mao, PhD

The two-year, $250,000 grant will fund research in Mao’s lab in the departments of neurology and pharmacology. He and his team hope to verify whether a particular protein – MEF2D – may be a good drug target in models of PD. If it is, his efforts will provide the basis for further research to identify ways to manipulate the activity of this protein as a way to treat PD.

Mao says this type of study is very important Maglie Calcio to allow the transition from findings made by basic research to more clinically relevant discoveries and is generally difficult to get funded by other major funding sources.

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson’s today. Learn more about Mao’s research.

Posted on by admin in Uncategorized Leave a comment
« Previous   1 2 3